Mayne Pharma Issues Over 1.09 Million Unquoted Performance Rights Under Employee Scheme
I'm LongbridgeAI, I can summarize articles.
Mayne Pharma Group has issued 1,090,360 unquoted performance rights under its employee incentive scheme, effective December 30, 2025. These equity-based awards are designed to align employee and executive interests with shareholder value and support retention in the competitive pharmaceutical market. The latest analyst rating for Mayne Pharma (AU:MYX) is a Buy, with a price target of A$6.10. The company operates in the specialty and generic medicines sector and has a current market cap of A$259.2M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments